Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intermediate filament family orphan 1 (IFFO1) is a structural protein of the intermediate filament family, encoded by the IFFO1 gene in humans. It is primarily associated with the cytoskeleton and nuclear envelope across various eukaryotic cell types[1][4]. IFFO1 acts as a nuclear matrix protein and is involved in immobilizing broken DNA ends, reducing chromosome translocation during DNA double-strand break (DSB) repair. The protein is recruited to sites of DNA damage in an XRCC4-dependent manner and forms a complex with XRCC4 and lamin A/C to create a nucleoskeleton, thereby stabilizing DNA ends and suppressing genome instability, particularly during tumorigenesis[2][4][5]. IFFO1 is widely expressed, with highest levels in the spleen, cerebellum, and cerebral cortex, and has several spliced isoforms. While structurally similar to vimentin, IFFO1 is evolutionarily conserved in vertebrates and possesses numerous post-translational modifications. There is currently no evidence implicating IFFO1 as a direct therapeutic drug target, nor are there clinically significant interacting drugs, biomarker applications, or described safety concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intermediate filament family orphan 1 (IFFO1).